Discovery of a novel 2-aminopyrazine-3-carboxamide as a potent and selective inhibitor of Activin Receptor-Like Kinase-2 (ALK2) for the treatment of fibrodysplasia ossificans progressiva.
Ullrich, Thomas, Teixeira-Fouchard, Sylvie, Broennimann, Valerie, Stiefl, Nikolaus, Head, Victoria, Kramer, Ina, Guth-Gundel, Sabine, Arista, Luca and Weiler, Sven (2022) Discovery of a novel 2-aminopyrazine-3-carboxamide as a potent and selective inhibitor of Activin Receptor-Like Kinase-2 (ALK2) for the treatment of fibrodysplasia ossificans progressiva. Bioorganic & medicinal chemistry letters. ISSN 1464-3405
Abstract
Inhibition of mutant activin A type-1 receptor ACVR1 (ALK2) signaling by small-molecule drugs is a promising therapeutic approach to treat fibrodysplasia ossificans progressiva (FOP), an ultra-rare disease leading to progressive soft tissue heterotopic ossification with no curative treatment available to date. Here, we describe the synthesis and in vitro characterization of a novel series of 2-aminopyrazine-3-carboxamides that led to the discovery of Compound 23 showing excellent biochemical and cellular potency, selectivity over other BMP and TGFβ signaling receptor kinases, and a favorable in vitro ADME profile.
Item Type: | Article |
---|---|
Date Deposited: | 29 Mar 2022 00:45 |
Last Modified: | 29 Mar 2022 00:45 |
URI: | https://oak.novartis.com/id/eprint/46717 |